Adenosine A2A Receptor: A Prognosis Marker For Lung Cancer
Since HIF-2alpha is too labile to be used as a marker, ADORA2A instead can be used as readout of HIF-2alpha activation and can be easily measured at the RNA level in biopsy samples.
A biomarker for HIF-2alpha activation and therefore for poor prognosis in lung cancer.A target for anti-angiogenic therapy in lung cancer
Adenosine A2A receptor expression is increased in lung tumor samples at different stages:(A) Human lung cancer expression panels (I and IV) containing reverse-transcribed cDNA from the different tumor stages were probed with real-time Taqman primers and probes for adenosine A2A receptor and CD31. The A2A expression data were normalized to CD31 expression. The different tumor stages were grouped together and plotted after log transformation. *, Statistical difference from the normal lung tissue using a 2-sample t test.(B) Normalized A2A expression data were plotted against the different stages of tumors. ANOVA was used to compare the groups, followed by pairwise comparisons of normal tissue versus each of the other groups using Dunnett's procedure. *, Statistically different from the normal lung tissue.(C) CC1-CC4 show significant positive CD31 (PECAM-1; pinkish-red) immunostaining in the bronchovascular bundles (CC1-CC3) and parenchyma (CC3 and CC4) of normal (atelectatic) lung tissue obtained at surgery. Staining of venous and/or lymphatic vessel endothelium (CC1, arrow) and arterial vessel endothelium (CC2 and CC3, arrowheads) was variable but notably positive, as was the capillary endothelium (CC3 and CC4). Immunostaining for adenosine receptor A2A (brown) was largely absent from these tissues. By contrast, lung cancer specimens from both of these patients (CT1, CT2, CT3, and CT4) stained markedly positive, especially in the tumor stroma. In these regions, CD31-positive-staining cells, likely endothelial cells and/or tumor macrophages, coimmunostained positively for adenosine receptor A2A or, in some cases, A2A-positive cells were immediately adjacent to those staining positively for CD31 (Magnification: 40X).Our scientists have found that:Hypoxia increases ADORA2A in vitroHIF-2alpha and not HIF-1alpha regulates ADORA2A expressionOverexpression of ADORA2A or its activation through agonists leads to an increase in endothelial cell proliferation, migration, and branchingADORA2A expression increases in later stage tumor samples collected from lung cancer patients
Inventor: AHMAD, Aftab | WHITE, Carl, W.
Priority Number: WO2009065044A2
IPC Current: C12N001510 | C12Q000168 | G01N0033574
Assignee Applicant: National Jewish Health
Title: MARKER FOR CANCER PROGNOSIS AND METHODS RELATED THERETO | MARQUEUR PRONOSTIQUE DU CANCER ET PROCÉDÉS ASSOCIÉS
Usefulness: MARKER FOR CANCER PROGNOSIS AND METHODS RELATED THERETO | MARQUEUR PRONOSTIQUE DU CANCER ET PROCÉDÉS ASSOCIÉS
Summary: The methods are useful for diagnosing a patient with a cancer that is associated with HIF-2α expression; identifying cancer patients with a poor prognosis for survival; identifying cancer patients with a high level of tumor aggressiveness; selecting a cancer patient who is predicted to benefit from therapeutic administration of an HIF-2α antagonist, an agonist, or a drug having substantially similar biological activity as the HIF-2α antagonist; selecting the cancer patient who is predicted to benefit from therapeutic administration of an antagonist of the PI3K/Akt signal transduction pathway; in vivo imaging for cancer diagnosis or prognosis; identifying the stage of lung development in a fetus or neonatal infant; modulating lung development in the fetus or neonatal infant; identifying agents that inhibit the development of pulmonary hypertension and related conditions; inhibiting the development of pulmonary hypertension and related conditions; inhibiting or promoting angiogenesis; and treating a disease that is associated with an increase in angiogenesis, where the disease is selected from cancer, diabetes, blindness, age-related macular degeneration, rheumatoid arthritis, and psoriasis, or for treating a disease that is associated with insufficient angiogenesis, where the disease is selected from coronary artery disease, stroke, and delayed wound healing (all claimed).
Novelty: Diagnosing a patient with a cancer that is associated with hypoxia-inducible transcription factor (HIF)-2alpha expression, by detecting the expression of adenosine A2A receptor (A2A), comparing the level of expression, and diagnosing
Disease Diagnostic/Treatment
Cancer/Tumor
USA
